Dri Healthcare Trust · TSX:DHT.U

Dri Healthcare Trust — Merger or Acquisition (August 2021)

8 slides from Dri Healthcare Trust's merger presentation, Aug 25, 2021

  1. Slide 1: Acquisition of pacritinib Royalty and CTI BioPharma Secured Loan

    Acquisition of pacritinib Royalty and CTI BioPharma Secured Loan August 25, 2021

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, busin

  3. Slide 3: Transaction Highlights

    TRANSACTION HIGHLIGHTS Medically necessary product / addresses unmet medical need Strong and long-lasting intellectual property Extends weighted average duration of royalty portfolio (to over 9 years) Within target deal size of US$25M to US$150M Synthetic royalty stream aligns with stated growth str

  4. Slide 4: Transaction Highlights

    TRANSACTION HIGHLIGHTS  Transaction demonstrates ability of DHT to acquire quality assets with “win-win” solutions through bespoke transaction structures that meet objectives of counterparties  Immediate deployment of US$50 million via secured loan, with overall deal size of US$110-US$135 million

  5. Slide 5: Transaction Terms

    TRANSACTION TERMS Secured long-term royalty  Senior secured loan of US$50 million to CTI BioPharma Corp. on stream on high quality closing product, with immediate  Interest rate of LIBOR plus 825 bps (subject to minimum 10.0%) contribution to cash flow  5-year term  Purchase of royalty on pacrit

  6. Slide 6: Myelofibrosis w/ Severe Thrombocytopenia

    MYELOFIBROSIS w/ SEVERE THROMBOCYTOPENIA  Myelofibrosis (MF) is a form of bone marrow cancer that can lead to thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver, with a median survival range of 2.25 – 11.25 years(1)  Thrombocytopenia (low blood platelet count) is an adver

  7. Slide 7: Pacritinib

    PACRITINIB  An investigational oral kinase inhibitor developed by CTI BioPharma Inc., with specificity for JAK2, IRAK1, and CSF1R  Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leu

  8. Slide 8: Summary and Outlook

    SUMMARY AND OUTLOOK  On track to deliver on growth targets  US$650 to US$750 million five-year Transaction aggregate acquisition target demonstrates our commitment and  Target sustainable growth in cash royalty ability to build receipts DRI’s asset base  Acquisition pipeline remains strong and g

DRI Healthcare Trust — Merger or Acquisition (August 2021) on 6ix